Pipeline — Biologic Therapeutic Candidates
| PRODUCT | DRUG CLASS | INDICATION | TARGET | PROGRESS | PARTNER | |||
|---|---|---|---|---|---|---|---|---|
| PRE-CLINICAL | PHASE I | PHASE II/III | MAA/BLA | |||||
EG12014* (EIRGASUN® / HERWENDA®) Trastuzumab biosimilar | Monoclonal Antibody | HER2+ Breast Cancer (BC) | HER 2 |  |  | |||
EG1206A Pertuzumab biosimilar | Monoclonal Antibody | HER2+ BC | HER 2 | | | |||
EG12043 (TSY110) Kadcyla biosimilar | Antibody Drug Conjugate (ADC) | HER2+ BC | HER 2 | |  | |||
EG13084 Phesgo (SC formulation) | Monoclonal Antibody | HER2+ BC | HER 2 | | - | |||
EG12112 Atezolizumab biosimilar | Monoclonal Antibody | Solid Tumors | PD-L1 | | - | |||
EG12164 Daratumumab biosimilar | Monoclonal Antibody | Myeloma | CD38 | | - | |||
EG7412F Hyaluronidase (rHuPH20) | Enzyme | N/A | High-dose mAb forms. | | - | |||
EG12170 Trastuzumab-deruxtecan biosimilar | Antibody Drug Conjugate | HER2+ BC | HER 2 | | | |||